These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35274775)

  • 1. Multicenter performance evaluation and reference range determination of a new one-stage factor VIII assay.
    Lowe AE; Jones R; Kitchen S; Geisen U; Rozsnyai G; Jilma P; Quehenberger P
    J Clin Lab Anal; 2022 Apr; 36(4):e24294. PubMed ID: 35274775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Chromogenic Factor VIII Assay Compared with One-Stage Clotting Assay.
    Akkaya E; Hatiboglu S; Koc B; Genc S; Unuvar A; Karaman S; Omer B; Karakas Z; Zulfikar B
    Clin Lab; 2020 Oct; 66(10):. PubMed ID: 33073956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the analytical performance of five new coagulation assays for the measurement of prothrombin time and activated thromboplastin time.
    Kitchen S; Geisen U; Kappelmayer J; Quehenberger P; Drieß J; Lowe A; Jones R; Boehm JG; Miles G; Rozsnyai G
    Int J Lab Hematol; 2018 Dec; 40(6):645-654. PubMed ID: 30033570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
    Ninivaggi M; Dargaud Y; van Oerle R; de Laat B; Hemker HC; Lindhout T
    J Thromb Haemost; 2011 Aug; 9(8):1549-55. PubMed ID: 21605333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.
    Ketteler C; Hoffmann I; Davidson S; Tiede A; Richter N
    Haemophilia; 2021 Nov; 27(6):e704-e712. PubMed ID: 34590394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
    Ingerslev J; Jankowski MA; Weston SB; Charles LA;
    J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A.
    Novembrino C; Boscolo Anzoletti M; Mancuso ME; Shinohara S; Peyvandi F
    Haemophilia; 2019 May; 25(3):521-526. PubMed ID: 31044485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter performance evaluation of the new Elecsys Vitamin D total III assay versus reference isotope dilution liquid chromatography tandem mass spectrometry and commercially available comparators.
    Findeisen P; Leis M; Bendig G; Grimme J; Moser E; Vogl C; Christenson R
    J Clin Lab Anal; 2022 Sep; 36(9):e24610. PubMed ID: 35852988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between coagulation factor VIII quantified with one-stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle.
    Donners AAMT; van Maarseveen EM; Weetink YRJ; El Amrani M; Fischer K; Rademaker CMA; Egberts TCG; Huisman A; Musson REA
    Int J Lab Hematol; 2020 Dec; 42(6):819-826. PubMed ID: 32633067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
    Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
    Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
    Hubbard AR; Rigsby P; Barrowcliffe TW
    Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.
    van Moort I; Meijer P; Priem-Visser D; van Gammeren AJ; Péquériaux NCV; Leebeek FWG; Cnossen MH; de Maat MPM
    Haemophilia; 2019 Jan; 25(1):162-169. PubMed ID: 30488994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.
    Turecek PL; Romeder-Finger S; Apostol C; Bauer A; Crocker-Buqué A; Burger DA; Schall R; Gritsch H
    Haemophilia; 2016 Nov; 22(6):957-965. PubMed ID: 27353010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).
    Shima M; Matsumoto T; Fukuda K; Kubota Y; Tanaka I; Nishiya K; Giles AR; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):436-41. PubMed ID: 11916076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience.
    Hegemann I; Koch K; Clausen WHO; Ezban M; Brand-Staufer B
    Acta Haematol; 2020; 143(5):504-508. PubMed ID: 31639805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.
    Sommer JM; Moore N; McGuffie-Valentine B; Bardan S; Buyue Y; Kamphaus GD; Konkle BA; Pierce GF
    Haemophilia; 2014 Mar; 20(2):294-300. PubMed ID: 24261554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay.
    Pouplard C; Caron C; Aillaud MF; Ternisien C; Desconclois C; Dubanchet A; Sobas F
    Haemophilia; 2011 Sep; 17(5):e958-62. PubMed ID: 21457408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
    Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
    Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Commutability of reference materials for coagulation factor VIII and factor IX activity on three measurement systems].
    Zhou W; Li C; Zhang H; Cheng F; Peng M
    Zhonghua Yi Xue Za Zhi; 2015 Sep; 95(34):2754-9. PubMed ID: 26711972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.